Two Clocks, One Drug: How Patents and FDA Exclusivity Actually Determine When Your Drug Faces Competition
Two clocks. One drug. And a lot of investors betting on the wrong one.
In pharma, timing isn’t just strategy—it’s destiny. Yet too many teams (and too many market narratives) treat “patent expiry” as the finish line. It isn’t.
A recent DrugPatentWatch …
